دورية أكاديمية
Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry
| العنوان: | Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry |
|---|---|
| المؤلفون: | Dierks, Raphaela Marie Louisa, Bruyère, Olivier, Reginster, Jean-Yves, Richy, Florent |
| المصدر: | Expert Review of Pharmacoeconomics and Outcomes Research, 16 (5), 571-8 (2016-10) |
| بيانات النشر: | Taylor & Francis, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Macro-economic factors, Business model, Pharmaceutical industry, Healthcare, Business & economic sciences, Macroeconomics & monetary economics, Human health sciences, Pharmacy, pharmacology & toxicology, Sciences économiques & de gestion, Macroéconomie & économie monétaire, Sciences de la santé humaine, Pharmacie, pharmacologie & toxicologie |
| الوصف: | Introduction: Technological innovations, new regulations, increasing costs of drug productions andnew demands are only few key drivers of a projected alternation in the pharmaceutical industry andits underlying business model. Despite significant articles in the press, there is little medical andeconomic evidence on the rationale driving the transformation from the traditional Research &Development (R&D) model to new alternative business models, such as Mergers & Acquisitions(M&A). The purpose of this review is to understand the macro-economic factors responsible for therevolution of the pharmaceutical business model, by understanding the needs, desires, newbehavioral patterns, but also challenges within the industry. Considering these changes will be thekey to possessing a competitive advantage over the market players.Areas covered: Existing literature on new macro-economic factors changing the pharmaceuticallandscape has been reviewed to present a clear image of the current market environment.Expert commentary: Literature and media sources show that pharmaceutical companies are facingan architectural alteration in their business model, with more M&A deals and collaborationsheadlining the papers. Although Q1 2016 did show a major slowdown in M&A deals by volume since2013 (with deal cancellations of Pfizer and Allergan, or the downfall of Valeant) pharmaceuticalanalysts remain confident that this shortfall was a consequence of the equity market volatility. Itseems likely that the shift to an M&A model will become apparent during the remainder of 2016,with deal announcements such as Abbott Laboratories, AbbVie and Sanofi worth USD 45billion [1]showing the appetite of big pharma companies to shift from the fully vertical integrated businessmodel to more horizontal business models. |
| نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501 article |
| اللغة: | English |
| Relation: | urn:issn:1473-7167; urn:issn:1744-8379 |
| DOI: | 10.1080/14737167.2016.1239534 |
| URL الوصول: | https://orbi.uliege.be/handle/2268/201964 |
| حقوق: | restricted access http://purl.org/coar/access_right/c_16ec info:eu-repo/semantics/restrictedAccess |
| رقم الأكسشن: | edsorb.201964 |
| قاعدة البيانات: | ORBi |
| DOI: | 10.1080/14737167.2016.1239534 |
|---|